# Novavax (NVAX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/NVAX
## Company Profile
- Ticker: NVAX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Vaccines, Recombinant Protein & VLP Vaccines
## Stock Data
- Close: 10.19 USD
- Market cap: 1678913194.9900002 USD
- Last updated: 2026-09-08
## Business Overview
Novavax is a vaccine company centered on protein-based immunization and respiratory-disease programs. Its story has been shaped by the challenge of turning platform science into durable commercial execution.
## Why The Stock Is Moving

As of Sep 8, 2026, NVAX closed down 0.29% at $10.19. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Novavax sits in specialty vaccine biotechnology.

## Business Model

The business depends on vaccine demand, partnerships, regulatory progress, and the ability to sustain a post-pandemic franchise.

## Landscape Position

Novavax is a vaccine catalyst name where commercial and regulatory updates can quickly shift sentiment.

## Future Catalysts

- Novavax's catalysts are the COVID/flu-combo program, seasonal-vaccine partnerships, and royalty momentum from its vaccine platform. The company still needs the platform to keep broadening.

## Recent News
- 2021-03-08 23:00 EST — [Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat](https://biopharmsignal.com/news/NVAX/novavax-to-participate-in-h-c-wainwright-virtual-global-life-sciences-conference-089716a7) — Source: Novavax
- 2021-03-01 21:02 EST — [Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights](https://biopharmsignal.com/news/NVAX/novavax-reports-fourth-quarter-and-full-year-2020-financial-results-and-operatio-7ef9cc50) — Source: Novavax
- 2021-03-01 12:11 EST — [ノヴァヴァックスと武田がノヴァヴァックスのCOVID-19ワクチン候補のライセンス契約を確定し、武田は日本で第I/Ⅱ相試験を開始](https://biopharmsignal.com/news/NVAX/covid-19-i-3c85a346) — Source: Novavax
- 2021-02-26 13:23 EST — [Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan](https://biopharmsignal.com/news/NVAX/novavax-and-takeda-finalize-license-agreement-for-novavax-covid-19-vaccine-candi-edc7c5fc) — Source: Novavax
- 2021-02-22 12:00 EST — [Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico](https://biopharmsignal.com/news/NVAX/novavax-completes-enrollment-of-prevent-19-covid-19-vaccine-pivotal-phase-3-tria-ee0f3d1d) — Source: Novavax